NCT05289687 2026-04-03Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLEastern Cooperative Oncology GroupPhase 2 Recruiting20 enrolled
NCT07072585 2025-12-31Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)Children's Oncology GroupPhase 2/3 Not yet recruiting1,708 enrolled